

ABSTRACT

The present invention is aiming to provide further advantageous effects on treating pancreas cancer, thus providing the means therefor is the subject. The present invention was obtained by finding that there were differences in prognosis in accordance with intrinsic IL-12-producing ability when Novel Immunotherapy for Cancer (NITC) was conducted in targeting pancreatic cancer cases, and further finding that extremely high effects could be obtained on pancreatic cancer therapy by selecting a therapy based on examination results of the level of intrinsic IL-12-producing ability. Therefore, the present invention is to provide an examination method to predict prognostic effects in immunotherapy for pancreas cancer, comprising determination of intrinsic IL-12-producing ability, and a therapeutic agent for pancreas cancer based on that.